Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease

OBJECTIVES: Isradipine is a dihydropyridine calcium channel inhibitor that has demonstrated concentration‐dependent neuroprotective effects in animal models of Parkinson’s disease (PD) but failed to show efficacy in a phase 3 clinical trial. The objectives of this study were to model the plasma phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Venuto, Charles S., Yang, Luoying, Javidnia, Monica, Oakes, David, James Surmeier, D., Simuni, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951102/
https://www.ncbi.nlm.nih.gov/pubmed/33460320
http://dx.doi.org/10.1002/acn3.51300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951102/
https://www.ncbi.nlm.nih.gov/pubmed/33460320
http://dx.doi.org/10.1002/acn3.51300

Ejemplares similares